GALECTIN THERAPEUTICS INC. - COMMON STOCK

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

30 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

16 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

02 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

24 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

05 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

29 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

28 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

14 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

01 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present in Upcoming Conferences

14 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

12 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

06 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

08 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

15 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

26 Jul 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

21 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

23 May 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

16 May 2022 07:00:02 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

14 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

31 Mar 2022 07:00:00 By Nasdaq GlobeNewswire